The use of cardiopulmonary bypass (CPB) is associated with the development of a significant systemic inflammatory response syndrome (SIRS) which can affect patient outcomes.
This article will review current ECPB techniques and explore its growing role in the treatment of severely hemodynamically compromised poisoned patients.